DOI QR코드

DOI QR Code

Incidence, mortality, and survival of liver cancer using Korea central cancer registry database: 1999-2019

  • Sung Yeon Hong (Department of Liver Transplantation and Hepatobiliary Surgery, Ajou University School of Medicine) ;
  • Mee Joo Kang (Division of Cancer Registration and Surveillance, National Cancer Center) ;
  • Taegyu Kim (Department of Liver Transplantation and Hepatobiliary Surgery, Ajou University School of Medicine) ;
  • Kyu-Won Jung (Division of Cancer Registration and Surveillance, National Cancer Center) ;
  • Bong-Wan Kim (Department of Liver Transplantation and Hepatobiliary Surgery, Ajou University School of Medicine)
  • Received : 2022.06.15
  • Accepted : 2022.07.12
  • Published : 2022.08.31

Abstract

Backgrounds/Aims: Historically, incidence and survival analysis and annual traits for primary liver cancer (LC) has not been investigated in a population-based study in Korea. The purpose of the current study is to determine incidence, survival rate of patients with primary LC in Korea. Methods: We conducted a retrospective cohort study using Korea Central Cancer Registry based on the Korea National Cancer Incidence Database. Statistical analysis including crude rate and age-standadized rate (ASR) of incidence and mortality was performed for LC patients registered with C22 code in International Classification of Diseases, tenth revision from 1999 to 2019. Subgroup analysis was performed for hepatocellular carcinoma (HCC, C22.0) and intrahepatic cholangiocarcinoma (IHCC, C22.1). Results: The crude incidence rate of HCC (21.0 to 22.8 per 100,000) and IHCC (2.3 to 5.6 per 100,000) increased in the observed period from 1999 to 2019. The ASR decreased in HCC (20.7 to 11.9 per 100,000) but remained unchanged in IHCC (2.4 to 2.7 per 100,000). The proportion of HCC patients diagnosed in early stages (localized or regional Surveillance, Epidemiology, and End Results or SEER stage) increased significantly over time. As expected, 5-yeat survival rate of HCC was greatly improved, reaching 42.4% in the period between 2013 and 2019. This trait was more prominent in localized SEER stage. On the other hand, the proportion of IHCC patients diagnosed in localized stage remained unchanged (22.9% between 2013 and 2019), although ASR and 5-year survival rate showed minor improvements. Conclusions: A great improvement in survival rate was observed in patients with newly diagnosed HCCs. It was estimated to be due to an increase in early detection rate. On the contrary, detection rate of an early IHCC was stagnant with a minor improvement in prognosis.

Keywords

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. Erratum in: CA Cancer J Clin 2020;70:313.
  2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E386. https://doi.org/10.1002/ijc.29210
  3. Sia D, Villanueva A, Friedman SL, Llovet JM. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology 2017;152:745-761. https://doi.org/10.1053/j.gastro.2016.11.048
  4. Kim BH, Park JW. Epidemiology of liver cancer in South Korea. Clin Mol Hepatol 2018;24:1-9. https://doi.org/10.3350/cmh.2017.0112
  5. Choi SI, Cho Y, Ki M, Kim BH, Lee IJ, Kim TH, et al. Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: changes in 16-years cohorts. PLoS One 2022;17:e0265668.
  6. Kim BH, Lee D, Jung KW, Won YJ, Cho H. Cause of death and cause-specific mortality for primary liver cancer in South Korea: a nationwide population-based study in hepatitis B virus-endemic area. Clin Mol Hepatol 2022;28:242-253. https://doi.org/10.3350/cmh.2021.0355
  7. Kang MJ, Won YJ, Lee JJ, Jung KW, Kim HJ, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2019. Cancer Res Treat 2022;54:330-344. https://doi.org/10.4143/crt.2022.128
  8. Yang MS, Park M, Back JH, Lee GH, Shin JH, Kim K, et al. Validation of cancer diagnosis based on the national health insurance service database versus the National Cancer Registry Database in Korea. Cancer Res Treat 2022;54:352-361. https://doi.org/10.4143/crt.2021.044
  9. Tanaka K, Ogura Y. "Small-for-size graft" and "small-for-size syndrome" in living donor liver transplantation. Yonsei Med J 2004;45:1089-1094. https://doi.org/10.3349/ymj.2004.45.6.1089
  10. Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery 2011;149:713-724. https://doi.org/10.1016/j.surg.2010.10.001
  11. Kang MJ, Lim J, Han SS, Park HM, Park SJ, Won YJ, et al. First course of treatment and prognosis of exocrine pancreatic cancer in Korea from 2006 to 2017. Cancer Res Treat 2022;54:208-217. https://doi.org/10.4143/crt.2021.421
  12. Strong RW. Living-donor liver transplantation: an overview. J Hepatobiliary Pancreat Surg 2006;13:370-377. https://doi.org/10.1007/s00534-005-1076-y
  13. Inomata Y, Uemoto S, Asonuma K, Egawa H. Right lobe graft in living donor liver transplantation. Transplantation 2000;69:258-264. https://doi.org/10.1097/00007890-200001270-00011
  14. Wong MC, Jiang JY, Goggins WB, Liang M, Fang Y, Fung FD, et al. International incidence and mortality trends of liver cancer: a global profile. Sci Rep 2017;7:45846.
  15. Yang S, Khang YH, Harper S, Davey Smith G, Leon DA, Lynch J. Understanding the rapid increase in life expectancy in South Korea. Am J Public Health 2010;100:896-903. https://doi.org/10.2105/AJPH.2009.160341
  16. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, et al. Nationwide cancer incidence in Korea, 1999~2001; first result using the national cancer incidence database. Cancer Res Treat 2005;37:325-331. https://doi.org/10.4143/crt.2005.37.6.325
  17. Kang MJ, Lim J, Han SS, Park HM, Kim SW, Won YJ, et al. Impact of changes in the topographic classification of Klatskin tumor on incidence of intra- and extrahepatic bile duct cancer: a population-based national cancer registry study. J Hepatobiliary Pancreat Sci 2021;28:740-750. https://doi.org/10.1002/jhbp.916